Gilead lays off 72 workers in Seattle, plans to shutter R&D support site

Roughly a year ago, Gilead Sciences revealed that it was laying off about 7% of Kite Pharma’s workforce in a bid to refresh its cell therapy subsidiary. Now, the Foster City, California-based pharma—best known for its HIV medicines—is telegraphing another round of job cuts.